Gastroenterology
Diverticular Disease
5
Pipeline Programs↗
1
Active Trials↗
4
Companies Involved↗
Diverticular Disease is an early-stage landscape with 5 programs across 4 companies. The most active players are Takeda, Salix, Ferring. 2 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 1
No programs
Phase 21
Phase 3
No programs
Analysis
Trial Status
7
clinical trials
Completed4 · 57%
Unknown status2 · 29%
Not yet recruiting1 · 14%
Clinical Trials
Trial Activity
7 trials
Clostridium Butyricum CBM588® vs. Rifaximin for Symptomatic Uncomplicated Diverticular Disease (SUDD): A Real-World Retrospective Study
Completed·—·N/A·NCT06852274·70 enrolled
Mesalamine for Uncomplicated Diverticular Disease: a Randomized, Double-blind, Placebo-controlled Study
Completed·—·Phase 2·NCT01627262·123 enrolled
Evaluation of the Metabolome in Diverticular Disease
Unknown status·—·N/A·NCT01831323·40 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)